What emerged across sessions at DTC National is that while DTC advertising remains a core driver of brand awareness, it is not consistently translating into predictable patient action.
Across multiple discussions, a more fragmented patient journey is clear. Patients moving directly from DTC exposure to action is unlikely. They search, hesitate, disengage, and re-engage across multiple touchpoints.
This creates a structural gap: DTC ads can generate exposure, but the channel does not reliably move patients forward by itself.
At the same time, teams are continuing to test how AI, creative, and omnichannel execution can better reflect lived experience to enable greater connection.
But alongside that, a more grounded reality has emerged as the US DTC advertising environment becomes more constrained, more complex, and less predictable.
How Is FDA Scrutiny Changing US DTC Marketing?
The most immediate force is regulatory.
In the US, prescription drug advertising is facing renewed bipartisan attention on Capitol Hill, with regulators pushing harder on fair balance and transparency.
FDA Commissioner Marty Makary reinforced in an opening session that while DTC advertising is not going away, it will continue to evolve. The shift is toward embedding critical information directly into the ad experience, rather than relying on disclosures that patients may overlook or not fully understand.
Today, only about a third of pharmaceutical social media ads include risk information—exactly the kind of gap the FDA is targeting.
At the same time, enforcement activity has increased. This signals a broader shift: in the US, compliance is no longer a guardrail. It is a central constraint shaping how DTC operates.
Why Are DTC Economics Becoming Less Predictable?
At the same time, DTC economics are becoming more challenging.
Media is more fragmented, less predictable, and more expensive. Linear TV, while still a core channel, no longer guarantees efficient reach on its own. Digital channels offer precision, but with tighter platform rules and less durable targeting.
The result is a tougher commercial equation: higher costs, more constrained messaging, and less certainty of return.
Where Does the Current DTC Model Start to Break Down?
When DTC ads are expected and assumed to generate awareness and drive patient action, the gap between exposure and action becomes harder to close.
DTC can create reach. It does not ensure progression.
Rather than treating the advertisement as the engine of growth, leading teams are beginning to view it as one input into a broader patient engagement system—one that supports patients across multiple decision points, not just episodic campaign moments.
What Changes When You Focus on Patient Experience, Not Campaign Performance?
Turning fragmented patient moments into a connected, guided journey is increasingly what’s required.
Yet many organizations are still asking, “How do we make DTC perform better?”
A more durable question is: how do we ensure that each patient interaction moves someone forward in their decision process?
This shifts the focus from campaign performance to patient progression.
How to Approach the Patient Journey Differently
Approaches like Reverba Global’s Patient Experience Engine are built around this shift.
Rather than relying primarily on broad-reach advertising, the focus is on identifying and engaging patients in high-intent, health-specific moments, often before or between traditional campaign touchpoints. It happens when they are actively researching symptoms, exploring conditions, or seeking information.
By supporting patients through key decision points, this approach helps address the drop-off between awareness and action that DTC alone cannot resolve.
The emphasis moves from generating awareness to driving progression across the patient journey.
As promotional messaging becomes more constrained in the US regulatory environment, context and relevance take on greater importance than persuasion alone. Educational, built-for-purpose engagement is better aligned with both regulatory expectations and patient behavior.
What Does This Mean for US Commercial Teams?
DTC isn’t going away, but it is losing its dominance as a standalone growth driver.
By itself, DTC cannot reliably drive patient progression. It must be integrated into a broader engagement model.
The companies that perform best will not simply be those with the most creative ads. They will be the ones that better capture and guide patient intent across the full patient journey.
Regulatory scrutiny in the US will continue to rise.
Media fragmentation will continue.
And patient expectations will continue to evolve.
In that environment, the question isn’t just how to make DTC work harder. It is how to build a system that works beyond it.
